A phase III study assessing Fluticasone ophthalmic for dry eye disease
Latest Information Update: 15 Mar 2024
At a glance
- Drugs Fluticasone propionate (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors NicOx
- 13 Mar 2024 According to NicOx media release, Company has agreed a development plan with the U.S. Food and Drug Administration (FDA) for a Phase 3 program in dry eye disease, and this asset is available for partnering outside China.
- 08 Feb 2022 According to NicOx media release, the company expects to initiate this study in 2023.
- 16 Oct 2020 New trial record